Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intest...
| Publicado en: | Digestive Diseases & Sciences Vol. 63; no. 4; pp. 825 - 834 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Apr2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128505529&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 128505529 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01632116 1VP jtl: Digestive Diseases & Sciences issn: 01632116 maglogo: N pubinfo: dt: Apr2018 vid: 63 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 128505529 128505529 NLM29484571 128505529 10.1007/s10620-018-4971-1 NLM29484571 128505529 ppf: 825 ppct: 9 formats: tig: atl: Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. aug: au: Fleisher, Mark Marsal, Jan Lee, Scott D. Frado, Laura E. Parian, Alyssa Korelitz, Burton I. Feagan, Brian G. affil: Borland-Groover Clinic, Jacksonville, FL, USA sug: subj: Inflammatory Bowel Diseases Drug Therapy Antibodies, Monoclonal Therapeutic Use Gastrointestinal Agents Therapeutic Use Inflammatory Bowel Diseases Complications Young Adult Adolescence Aged, 80 and Over Adult Middle Age Female Male Arthritis Impact Measurement Scales Adolescent: 13-18 years Aged, 80 & over Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action.Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action.Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn's disease.Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|